Sarepta Therapeutics Inc [NASDAQ: SRPT] surged by $0.63 during the normal trading session on Tuesday and reaching a high of $18.84 during the day while it closed the day at $18.1.
Sarepta Therapeutics Inc stock has also gained 2.61% of its value over the past 7 days. However, SRPT stock has declined by -13.56% in the 3 months of the year. Over the past six months meanwhile, it has lost -82.14% and lost -85.56% year-on date.
The market cap for SRPT stock reached $1.77 billion, with 97.71 million shares outstanding and 92.34 million shares in the current float. Compared to the average trading volume of 12.99M shares, SRPT reached a trading volume of 6328303 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sarepta Therapeutics Inc [SRPT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRPT shares is $23.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRPT stock is a recommendation set at 2.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Sarepta Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 29, 2025. The new note on the price target was released on July 29, 2025, representing the official price target for Sarepta Therapeutics Inc stock. Previously, the target price had yet another raise to $22, while Barclays analysts kept a Equal Weight rating on SRPT stock.
The Price to Book ratio for the last quarter was 1.30, with the Price to Cash per share for the same quarter was set at 8.19.
SRPT stock trade performance evaluation
Sarepta Therapeutics Inc [SRPT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.61. With this latest performance, SRPT shares dropped by -17.01% in over the last four-week period, additionally sinking by -82.14% over the last 6 months – not to mention a drop of -85.11% in the past year of trading.
Sarepta Therapeutics Inc [SRPT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sarepta Therapeutics Inc [SRPT] shares currently have an operating margin of -0.04% and a Gross Margin at 77.63%. Sarepta Therapeutics Inc’s Net Margin is presently recorded at -2.34%.
Sarepta Therapeutics Inc (SRPT) Capital Structure & Debt Analysis
According to recent financial data for Sarepta Therapeutics Inc. ( SRPT), the Return on Equity (ROE) stands at -4.76%, reflecting a slight decline for investors. The Return on Assets (ROA) is -1.63%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Sarepta Therapeutics Inc’s Return on Invested Capital (ROIC) is -2.14%, showcasing its effectiveness in deploying capital for earnings.
Sarepta Therapeutics Inc (SRPT) Efficiency & Liquidity Metrics
Based on Sarepta Therapeutics Inc’s (SRPT) latest financial statements, the Debt-to-Equity Ratio is 1.00%, indicating its reliance on debt financing relative to shareholder equity.
Sarepta Therapeutics Inc (SRPT) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Sarepta Therapeutics Inc. (SRPT) effectively leverages its workforce, generating an average of -$42244.9 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.89% and a Quick Ratio of 1.81%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Sarepta Therapeutics Inc [SRPT] stock
With the latest financial reports released by the company, Sarepta Therapeutics Inc posted 0.62/share EPS, while the average EPS was predicted by analysts to be reported at 0.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.25. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRPT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sarepta Therapeutics Inc go to 4.48%.
Sarepta Therapeutics Inc [SRPT]: Institutional Ownership
There are presently around $81.82%, or 85.82%% of SRPT stock, in the hands of institutional investors. The top three institutional holders of SRPT stocks are: BLACKROCK INC. with ownership of 10.32 million shares, which is approximately 10.9117%. VANGUARD GROUP INC, holding 9.04 million shares of the stock with an approximate value of $$1.43 billion in SRPT stocks shares; and VANGUARD GROUP INC, currently with $$682.69 million in SRPT stock with ownership which is approximately 4.5666%.
